Author Archives: William Looney

Can Sanofi's Expanding Predictive Modeling Technology Enhance the Productivity of R&D?

By William Looney | Published: February 15, 2012
As the hurdles to successful commercialization of new medicines continue to mount, the ability to find and exploit cost efficiencies in the development process has become a critical source of competitive advantage.  This is true not only for biologic drugs but also increasingly for vaccines, now a high growth segment of the medicines business, with [...]
Posted in Biotech | Tagged , , , | Leave a comment

Medical Economics: New Highs for a Historic Brand

By William Looney | Published: February 9, 2012
Medical Economics has been named "Media Brand of the Year" but MM&M magazie, one of sister publication Pharm Exec's main competitors.
Posted in Advertising, Biotech, E-Media, Marketing, Medical Education, Strategy, healthcare | Tagged , , , , | Leave a comment

HBA 2012 Woman of the Year: Thinking Beyond the Box

By William Looney | Published: February 3, 2012
The Healthcare Businesswomen’s Association (HBA) has announced that its 2012 Woman of the Year (WOTY) is Carolyn Buck Luce, global pharmaceutical sector leader at Ernst & Young.  She will be honored at the HBA’s annual Woman of the Year luncheon on May 3 in New York – the 23rd recipient from an organization that has set the pace in [...]
Posted in Strategy | 1 Comment

PCORI, Priorities, and Politics

By William Looney | Published: February 1, 2012
William Looney looks at the three P’s of effectiveness  research:  PCORI, Priorities, and Politics If you ever wanted to know what health economists might do with a billion dollars, the Obama Administration’s  Patient-Centered Outcomes Research Institute [PCORI] is about to tell all:  not right down to the penny, but good enough.  The congressionally funded – [...]
Posted in Regulatory, healthcare | Tagged , , , , | Leave a comment

Calculating the Cost of R&D: Defending Tufts Research

By William Looney | Published: January 11, 2012
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues,  because if you cannot justify your costs how do you expect to prevail on price?   
Posted in Op-Ed, R&D, pricing | Tagged , , , , , | 1 Comment